Disease · MONDO_0009061
Comparisons in its trials165
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 165
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ELX/TEZ/IVA vs VX-121/TEZ/D-IVA: deaths from any cause | 0 of 289 | 0 of 284 | 573 | NCT05076149 | Trial comparisons |
| ELX/TEZ/IVA vs VX-121/TEZ/D-IVA: serious adverse events | 40 of 289 | 40 of 284 | 573 | NCT05076149 | Trial comparisons |
| Part A: ELX/TEZ/IVA vs Part B: ELX/TEZ/IVA: deaths from any cause | 0 of 457 | 0 of 66 | 523 | NCT04043806 | Trial comparisons |
| Part A: ELX/TEZ/IVA vs Part B: ELX/TEZ/IVA: serious adverse events | 75 of 457 | 4 of 66 | 523 | NCT04043806 | Trial comparisons |
| Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation (TOBI): serious adverse events | 85 of 308 | 61 of 209 | 517 | NCT00388505 | Trial comparisons |
| Treatment Period: ELX/TEZ/IVA vs Extension Period: ELX/TEZ/IVA: deaths from any cause | 1 of 506 | 0 of 11 | 517 | NCT03525574 | Trial comparisons |
| Treatment Period: ELX/TEZ/IVA vs Extension Period: ELX/TEZ/IVA: serious adverse events | 175 of 506 | 0 of 11 | 517 | NCT03525574 | Trial comparisons |
| VX-661/IVA vs Placebo: deaths from any cause | 0 of 251 | 0 of 258 | 509 | NCT02347657 | Trial comparisons |
| VX-661/IVA vs Placebo: serious adverse events | 31 of 251 | 47 of 258 | 509 | NCT02347657 | Trial comparisons |
| VX-661/IVA vs Placebo: Number of Participants With at Least One Pulmonary Exacerbation Pulmonary Exacerbation Through Week 24 | 62 of 248 | 88 of 256 | 504 | NCT02347657 | Trial comparisons |
| Experimental Arm A vs Arm B - Control: The Incidence of Pulmonary Exacerbations | 28 of 209 | 29 of 214 | 423 | NCT02134353 | Trial comparisons |
| Experimental Arm A vs Arm B - Control: deaths from any cause | 0 of 207 | 1 of 213 | 420 | NCT02134353 | Trial comparisons |
| Experimental Arm A vs Arm B - Control: serious adverse events | 31 of 207 | 29 of 213 | 420 | NCT02134353 | Trial comparisons |
| VX-445/TEZ/IVA TC vs Placebo: deaths from any cause | 0 of 202 | 0 of 201 | 403 | NCT03525444 | Trial comparisons |
| VX-445/TEZ/IVA TC vs Placebo: serious adverse events | 28 of 202 | 42 of 201 | 403 | NCT03525444 | Trial comparisons |
| ELX/TEZ/IVA vs VNZ/TEZ/D-IVA: deaths from any cause | 0 of 202 | 0 of 196 | 398 | NCT05033080 | Trial comparisons |
| ELX/TEZ/IVA vs VNZ/TEZ/D-IVA: serious adverse events | 41 of 202 | 28 of 196 | 398 | NCT05033080 | Trial comparisons |
| VX-659/TEZ/IVA TC vs Placebo: deaths from any cause | 0 of 193 | 0 of 189 | 382 | NCT03447249 | Trial comparisons |
| VX-659/TEZ/IVA TC vs Placebo: serious adverse events | 11 of 193 | 58 of 189 | 382 | NCT03447249 | Trial comparisons |
| Part A: ELX/TEZ/IVA vs Part B: ELX/TEZ/IVA: deaths from any cause | 1 of 251 | 0 of 84 | 335 | NCT04058366 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0009061/comparisons